Christian P Meyer1, Klaus Pantel2, Pierre Tennstedt1, Petra Stroelin1, Thorsten Schlomm1, Hans Heinzer1, Sabine Riethdorf2, Thomas Steuber3. 1. Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 3. Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: steuber@uke.de.
Abstract
INTRODUCTION: The presence of circulating tumor cells (CTCs) is an established marker for prognosis in men with castration-resistant prostate cancer. A cutoff of ≥5 CTCs/7.5ml blood in the CellSearch Epithelial Cell Test has been shown to stratify prognostic groups and predict outcome of abiraterone treatment. In contrast, the value of CTC detection in men with localized prostrate cancer before radical prostatectomy (RP) is unknown. MATERIALS AND METHODS: A total of 152 patients treated with RP between 06/2009 and 09/2009 were included. Peripheral venous blood drawn the day before RP was evaluated for CTCs by the CellSearch system. The detection of CTCs was correlated with prostate-specific antigen (PSA) and the histopathological outcome of the RP specimen. A cutoff of 0 vs. ≥1 CTC/7.5ml blood was defined as the threshold for positive vs. negative CTC status. RESULTS: Median age was 62 years and median PSA was 6.7ng/dl. Staging revealed 62.5% pT2, 26.3% pT3a, and 11.2% pT3b tumors, and high-grade disease (≥Gleason 4+3) was determined in 25.6% of patients. CTCs were detected in 17 patients (11%) with a median CTC count/7.5ml of 1 (range: 1-clusters with>100 epithelial cells) without significant correlations to PSA levels, pT stage, or Gleason scores. Postoperative pT stage was a significant predictor of biochemical recurrence (BCR) in univariable logistic regression models and as a composite measure together with positive CTC counts (P<0.0001). CTC positivity alone tended to have a higher hazard ratio for BCR, but this was not statistically significant (P = 0.1). After a median follow-up of 48 months, there was no significant difference in BCR-free survival between patients with or without CTCs (P = 0.7). CONCLUSION: Using the CellSearch system, we infrequently detected CTCs in patients with localized tumors before RP. The detection of CTCs did not correlate significantly with PSA, disease characteristics, or the development of BCR. However, larger cohorts with extended follow-up are needed to validate our findings.
INTRODUCTION: The presence of circulating tumor cells (CTCs) is an established marker for prognosis in men with castration-resistant prostate cancer. A cutoff of ≥5 CTCs/7.5ml blood in the CellSearch Epithelial Cell Test has been shown to stratify prognostic groups and predict outcome of abiraterone treatment. In contrast, the value of CTC detection in men with localized prostrate cancer before radical prostatectomy (RP) is unknown. MATERIALS AND METHODS: A total of 152 patients treated with RP between 06/2009 and 09/2009 were included. Peripheral venous blood drawn the day before RP was evaluated for CTCs by the CellSearch system. The detection of CTCs was correlated with prostate-specific antigen (PSA) and the histopathological outcome of the RP specimen. A cutoff of 0 vs. ≥1 CTC/7.5ml blood was defined as the threshold for positive vs. negative CTC status. RESULTS: Median age was 62 years and median PSA was 6.7ng/dl. Staging revealed 62.5% pT2, 26.3% pT3a, and 11.2% pT3b tumors, and high-grade disease (≥Gleason 4+3) was determined in 25.6% of patients. CTCs were detected in 17 patients (11%) with a median CTC count/7.5ml of 1 (range: 1-clusters with>100 epithelial cells) without significant correlations to PSA levels, pT stage, or Gleason scores. Postoperative pT stage was a significant predictor of biochemical recurrence (BCR) in univariable logistic regression models and as a composite measure together with positive CTC counts (P<0.0001). CTC positivity alone tended to have a higher hazard ratio for BCR, but this was not statistically significant (P = 0.1). After a median follow-up of 48 months, there was no significant difference in BCR-free survival between patients with or without CTCs (P = 0.7). CONCLUSION: Using the CellSearch system, we infrequently detected CTCs in patients with localized tumors before RP. The detection of CTCs did not correlate significantly with PSA, disease characteristics, or the development of BCR. However, larger cohorts with extended follow-up are needed to validate our findings.
Authors: David T Miyamoto; Richard J Lee; Mark Kalinich; Joseph A LiCausi; Yu Zheng; Tianqi Chen; John D Milner; Erin Emmons; Uyen Ho; Katherine Broderick; Erin Silva; Sarah Javaid; Tanya Todorova Kwan; Xin Hong; Douglas M Dahl; Francis J McGovern; Jason A Efstathiou; Matthew R Smith; Lecia V Sequist; Ravi Kapur; Chin-Lee Wu; Shannon L Stott; David T Ting; Anita Giobbie-Hurder; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber Journal: Cancer Discov Date: 2018-01-04 Impact factor: 39.397
Authors: Esther Campos-Fernández; Letícia S Barcelos; Aline Gomes de Souza; Luiz R Goulart; Vivian Alonso-Goulart Journal: Am J Cancer Res Date: 2019-07-01 Impact factor: 6.166
Authors: Zuzana Bielčiková; Anna Jakabová; Michael Pinkas; Milada Zemanová; Katarína Kološtová; Vladimír Bobek Journal: Am J Transl Res Date: 2017-06-15 Impact factor: 4.060
Authors: Luis León-Mateos; María Vieito; Urbano Anido; Rafael López López; Laura Muinelo Romay Journal: Int J Mol Sci Date: 2016-09-20 Impact factor: 5.923
Authors: Ignacio Puche-Sanz; María J Alvarez-Cubero; Manrique Pascual-Geler; Alba Rodríguez-Martínez; Miguel Delgado-Rodríguez; José L García-Puche; José Expósito; Inmaculada Robles-Fernández; Carmen Entrala-Bernal; José A Lorente; José M Cózar-Olmo; María J Serrano Journal: Oncotarget Date: 2017-07-31